Alder BioPharma (ALDR) Misses Q1 EPS by 104c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Alder BioPharma (ALDR) Misses Q1 EPS by 104c

Alder BioPharma (ALDR) Announces Positive Phase 2b Study Data for Eptinezumab at AAN Meeting

April 28, 2017 2:28 PM EDT

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of positive data from its Phase 2b clinical trial evaluating eptinezumab (formerly ALD403) for the prevention of migraine.

Key findings from the study showed that chronic migraine patients treated with a single infusion of eptinezumab (ALD403) experienced a significant reduction in migraine days as measured by 75% responder rates, with maximum efficacy in 1 to 4 weeks that was maintained through 12-weeks. Post hoc analysis of the trial data also suggested that a single administration led to a clinically... More